Editas Medicine
EDIT
201 hedge funds and large institutions have $918M invested in Editas Medicine in 2019 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 66 increasing their positions, 46 reducing their positions, and 28 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
43% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 46
29% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 28
17% more capital invested
Capital invested by funds: $784M → $918M (+$134M)
4.33% more ownership
Funds ownership: 72.11% → 76.45% (+4.3%)
4% more funds holding
Funds holding: 194 → 201 (+7)
73% less call options, than puts
Call options by funds: $7.03M | Put options by funds: $26.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$34.7M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$16.7M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$16.3M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 5 |
GLA
Great Lakes Advisors
Chicago,
Illinois
|
+$6.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.37M |
| 3 |
JCM
JS Capital Management
New York
|
-$4.98M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$3.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$3.46M |
EDIT Hedge Fund Activity: Q1 2019 in Review
201 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2019, worth a combined $918M — up 17% from $784M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new EDIT positions and 28 closed out — a net gain of 8 holders — while 66 added to existing stakes and 46 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $34.7M. The largest seller was Fidelity Investments, cutting an estimated $11.5M.
- 201 institutional investors held Editas Medicine (EDIT) as of Q1 2019, up from 194 in Q4 2018.
- Funds reported $918M of Editas Medicine stock for Q1 2019, up 17% quarter-over-quarter.
- 36 funds opened new Editas Medicine positions in Q1 2019 and 28 closed out, a net change of +8 holders.
- The largest Editas Medicine buyer in Q1 2019 was ARK Investment Management, an estimated $34.7M added.
- The largest Editas Medicine seller in Q1 2019 was Fidelity Investments, an estimated $11.5M sold.
Based on aggregated 13F filings for Q1 2019.